{"id":"NCT00702650","sponsor":"Eli Lilly and Company","briefTitle":"A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations","officialTitle":"A Phase III Open-label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-LotionÂ® (Cutaneous Solution) in Hypogonadal Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2008-06-20","resultsPosted":"2011-01-05","lastUpdate":"2011-07-25"},"enrollment":155,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism"],"interventions":[{"type":"DRUG","name":"Testosterone MD-Lotion","otherNames":["LY900011","Axiron"]}],"arms":[{"label":"Testosterone MD-Lotion","type":"EXPERIMENTAL"}],"summary":"Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product- Testosterone MD-Lotion (cutaneous solution), and this study will evaluate the efficacy via pharmacokinetics of various doses of this product. The study will also assess safety of the product.","primaryOutcome":{"measure":"Percentage of Participants With 24-Hour Average Concentration [Cavg(0-24h)] Total Testosterone Within Normal Range at Day 120","timeFrame":"Day 120","effectByArm":[{"arm":"Testosterone MD-Lotion","deltaMin":84.1,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":27,"countries":["United States","Australia","France","Germany","Sweden","United Kingdom"]},"refs":{"pmids":["21689131","26549704"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":155},"commonTop":["Application site irritation","Application site erythema","Headache","Nasopharyngitis","Haematocrit increased"]}}